H.C. Wainwright analyst Andrew Fein maintained a Buy rating on C4 Therapeutics on Tuesday, setting a price target of $63, which is approximately 63.68% above the present share price of $38.49.
Fein expects C4 Therapeutics to post earnings per share (EPS) of -$0.49 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in C4 Therapeutics, with an average price target of $58.67.
The analysts price targets range from a high of $63 to a low of $53.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $7.43 million and a net profit of -$20.51 million. The company's market cap is $1.66 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.0% and a 53.69% success rate.
C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.